RESEARCHER PROFILE
Remo Panaccione
← Back to University of Calgary
R
University of Calgary
Remo Panaccione works in Inflammatory Bowel Disease, Ocular Diseases and Behçet’s Syndrome, Rheumatoid Arthritis Research and Therapies, Microscopic Colitis, Psoriasis: Treatment and Pathogenesis. Recorded institutional associations include University of Calgary.
1,327Publications
63,835Citations
108H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
2017 · 6,054 citationsIncreasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review
2011 · 4,822 citationsAdalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
2006 · 2,245 citationsSelecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
2015 · 1,844 citationsHuman Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial
2006 · 1,715 citationsUstekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
2019 · 1,219 citationsThe natural history of fistulizing Crohn's disease in Olmsted County, Minnesota
2002 · 1,144 citationsUstekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
2012 · 1,134 citationsAdalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
2007 · 1,039 citationsCrohn’s disease
2020 · 1,023 citationsAdalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab
2007 · 965 citationsCombination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
2013 · 963 citationsNatalizumab Induction and Maintenance Therapy for Crohn's Disease
2005 · 927 citationsEffect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
2017 · 921 citationsRisk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies
2013 · 892 citationsAdalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
2011 · 892 citationsThe safety of vedolizumab for ulcerative colitis and Crohn's disease
2016 · 806 citationsUpadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
2022 · 643 citationsNatalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial
2007 · 614 citationsAdalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
2012 · 591 citationsInvasive potential of gut mucosa-derived fusobacterium nucleatum positively correlates with IBD status of the host
2011 · 573 citationsUpadacitinib Induction and Maintenance Therapy for Crohn’s Disease
2023 · 483 citationsEarly combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
2015 · 460 citationsAssociation of host genome with intestinal microbial composition in a large healthy cohort
2016 · 457 citationsGlobal evolution of inflammatory bowel disease across epidemiologic stages
2025 · 455 citations
